Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 11/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979699 | 0.88 | DAO (0.63) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL6790693 | 0.86 | GSK3B (0.66) | DAOGSK3BKDRMAPTNPSR1 | |
| SCHEMBL28474265 | 0.83 | DAO (0.57) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL15979708 | 0.82 | DAO (0.52) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL6917802 | 0.81 | DAO (0.60) | DAOGSK3BNPSR1 | |
| SCHEMBL3867877 | 0.81 | DAO (0.55) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL15979698 | 0.80 | GSK3B (0.62) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL3752532 | 0.79 | DAO (0.61) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL15547606 | 0.77 | DAO (0.59) | DAOGSK3BKDRCASP3SENP7 | |
| SCHEMBL26970953 | 0.77 | DAO (0.59) | DAOGSK3BKDRCASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | DAO 2816/4885GSK3B 1828/4885KDR 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.